Preclinical in-vitro and in-vivo studies of RDEA119 have demonstrated synergistic activity across multiple tumor types when RDEA119 is used in combination with other anticancer agents, including sorafenib.
This Phase I/II study in patients with advanced cancer will evaluate the safety, tolerability, pharmacokinetics and anti-tumor activity of RDEA119 in combination with Nexavar.
Barry Quart, president and CEO of Ardea, said: “RDEA119 represents an exciting, new opportunity in cancer treatment. The synergistic activity that we have seen in preclinical studies of RDEA119 in combination with a broad range of anticancer agents suggests that RDEA119 has the potential to enhance the current standard-of-care across multiple cancer indications.”